ArticleCancer chemotherapy and pharmacology2024

PARP1 promotes EGFR-TKI drug-resistance via PI3K/AKT pathway in non-small-cell lung cancer.

Xianping Xu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.